Table 1 summarizes the patient baseline characteristics; 89 patients with HER2-negative cancer received first line fluoropyrimidine/platinum chemotherapy (XELOX [n = 57], FOLFOX [n = 24], SP [n = 2], XP [n = 6]), and 10 patients with HER2-positive cancer received trastuzumab and XP (n = 7) or FP (n = 3). The gene discussed is ERBB2; the disease is cancer.